{"transactions":[{"id":2965941,"issuer":{"id":5892,"kind":"organization","name":"Opus Genetics, Inc.","symbol":"IRD"},"owners":[{"id":145064,"kind":"person","name":"MEYER ALAN R","position":1,"cik":"0001212162","reported_name":"MEYER ALAN R","relationship":{"director":true}}],"security":"Series B Warrant (right to buy)","published_at":"2020-11-26T00:42:10.000Z","date":"2020-11-19","kind":"purchase","acquired":true,"shares":315,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Subject to adjustment based on certain price reset provisions."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Reporting Person purchased shares, Series A Warrants and Series B Warrants as part of a private placement for an aggregate price of $10,000."}],"balance_after":315,"derivative":{"exercise_price":0.0001,"exercise_date":"2020-11-19","expiration_date":"2022-01-28","underlying":"Common Stock","underlying_shares":315},"source":{"system":"sec-edgar","filing":"0001140361-20-026650","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1228627/000114036120026650/form4.xml","form_type":"4"}},{"id":2965940,"issuer":{"id":5892,"kind":"organization","name":"Opus Genetics, Inc.","symbol":"IRD"},"owners":[{"id":145064,"kind":"person","name":"MEYER ALAN R","position":1,"cik":"0001212162","reported_name":"MEYER ALAN R","relationship":{"director":true}}],"security":"Series A Warrant (right to buy)","published_at":"2020-11-26T00:42:10.000Z","date":"2020-11-19","kind":"purchase","acquired":true,"shares":2679,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Subject to adjustment based on certain price reset provisions."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Reporting Person purchased shares, Series A Warrants and Series B Warrants as part of a private placement for an aggregate price of $10,000."}],"balance_after":2679,"derivative":{"exercise_price":4.4795,"exercise_date":"2020-11-19","expiration_date":"2025-11-19","underlying":"Common Stock","underlying_shares":2679},"source":{"system":"sec-edgar","filing":"0001140361-20-026650","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1228627/000114036120026650/form4.xml","form_type":"4"}},{"id":2965939,"issuer":{"id":5892,"kind":"organization","name":"Opus Genetics, Inc.","symbol":"IRD"},"owners":[{"id":145064,"kind":"person","name":"MEYER ALAN R","position":1,"cik":"0001212162","reported_name":"MEYER ALAN R","relationship":{"director":true}}],"security":"Common Stock","published_at":"2020-11-26T00:42:10.000Z","date":"2020-11-19","kind":"purchase","acquired":true,"shares":1771,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Reporting Person purchased shares, Series A Warrants and Series B Warrants as part of a private placement for an aggregate price of $10,000."}],"balance_after":487029,"source":{"system":"sec-edgar","filing":"0001140361-20-026650","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1228627/000114036120026650/form4.xml","form_type":"4"}},{"id":2980854,"issuer":{"id":5892,"kind":"organization","name":"Opus Genetics, Inc.","symbol":"IRD"},"owners":[{"id":145064,"kind":"person","name":"MEYER ALAN R","position":1,"cik":"0001212162","reported_name":"MEYER ALAN R","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2020-11-13T21:50:26.000Z","date":"2020-11-11","kind":"grant","acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vesting in 12 equal monthly increments beginning on November 30, 2020."}],"balance_after":7500,"derivative":{"exercise_price":4.05,"expiration_date":"2030-11-11","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001140361-20-025517","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1228627/000114036120025517/form4.xml","form_type":"4"}},{"id":2988094,"issuer":{"id":5892,"kind":"organization","name":"Opus Genetics, Inc.","symbol":"IRD"},"owners":[{"id":145064,"kind":"person","name":"MEYER ALAN R","position":1,"cik":"0001212162","reported_name":"MEYER ALAN R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-11-09T23:47:17.000Z","date":"2020-11-05","kind":"grant","acquired":true,"shares":31695,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reporting person acquired the shares and options to acquire shares of the common stock of Rexahn Pharmaceuticals, Inc. (\"Rexahn\") on November 5, 2020, in exchange for shares and options to acquire shares of the common stock of Ocuphire Pharma, Inc. (\"Ocuphire\"), pursuant to the Agreement and Plan of Merger and Reorganization, dated as of June 17, 2020, as amended, between Rexahn, Razor Merger Sub, Inc., and Ocuphire pursuant to which Ocuphire became a wholly-owned subsidiary of Rexahn. Per the terms of the Merger Agreement, each share of Ocuphire common stock was converted into the right to receive 1.0565 shares of Rexahn common stock. Subsequent to the merger, the name of the issuer was changed from Rexahn Pharmaceuticals, Inc. to Ocuphire Pharma, Inc."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"3,803 shares vested on December 31, 2019, and the remaining shares vest in equal monthly installments from January 2020 through December 2021, subject to continued service."}],"balance_after":31695,"derivative":{"exercise_price":1.21,"expiration_date":"2029-12-27","underlying":"Common Stock","underlying_shares":31695},"source":{"system":"sec-edgar","filing":"0001596771-20-000114","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1228627/000159677120000114/primary_doc.xml","form_type":"4"}},{"id":2988093,"issuer":{"id":5892,"kind":"organization","name":"Opus Genetics, Inc.","symbol":"IRD"},"owners":[{"id":145064,"kind":"person","name":"MEYER ALAN R","position":1,"cik":"0001212162","reported_name":"MEYER ALAN R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-11-09T23:47:17.000Z","date":"2020-11-05","kind":"grant","acquired":true,"shares":35663,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reporting person acquired the shares and options to acquire shares of the common stock of Rexahn Pharmaceuticals, Inc. (\"Rexahn\") on November 5, 2020, in exchange for shares and options to acquire shares of the common stock of Ocuphire Pharma, Inc. (\"Ocuphire\"), pursuant to the Agreement and Plan of Merger and Reorganization, dated as of June 17, 2020, as amended, between Rexahn, Razor Merger Sub, Inc., and Ocuphire pursuant to which Ocuphire became a wholly-owned subsidiary of Rexahn. Per the terms of the Merger Agreement, each share of Ocuphire common stock was converted into the right to receive 1.0565 shares of Rexahn common stock. Subsequent to the merger, the name of the issuer was changed from Rexahn Pharmaceuticals, Inc. to Ocuphire Pharma, Inc."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option is fully vested."}],"balance_after":35663,"derivative":{"exercise_price":0.9,"expiration_date":"2028-10-01","underlying":"Common Stock","underlying_shares":35663},"source":{"system":"sec-edgar","filing":"0001596771-20-000114","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1228627/000159677120000114/primary_doc.xml","form_type":"4"}},{"id":2988092,"issuer":{"id":5892,"kind":"organization","name":"Opus Genetics, Inc.","symbol":"IRD"},"owners":[{"id":145064,"kind":"person","name":"MEYER ALAN R","position":1,"cik":"0001212162","reported_name":"MEYER ALAN R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-11-09T23:47:17.000Z","date":"2020-11-05","kind":"grant","acquired":true,"shares":485258,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reporting person acquired the shares and options to acquire shares of the common stock of Rexahn Pharmaceuticals, Inc. (\"Rexahn\") on November 5, 2020, in exchange for shares and options to acquire shares of the common stock of Ocuphire Pharma, Inc. (\"Ocuphire\"), pursuant to the Agreement and Plan of Merger and Reorganization, dated as of June 17, 2020, as amended, between Rexahn, Razor Merger Sub, Inc., and Ocuphire pursuant to which Ocuphire became a wholly-owned subsidiary of Rexahn. Per the terms of the Merger Agreement, each share of Ocuphire common stock was converted into the right to receive 1.0565 shares of Rexahn common stock. Subsequent to the merger, the name of the issuer was changed from Rexahn Pharmaceuticals, Inc. to Ocuphire Pharma, Inc."}],"balance_after":485258,"source":{"system":"sec-edgar","filing":"0001596771-20-000114","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1228627/000159677120000114/primary_doc.xml","form_type":"4"}}]}